Published in Eur J Nucl Med Mol Imaging on January 18, 2012
FluoroAv45 Imaging Research-in Alzheimer's Disease (FAIR-AD) | NCT01325259
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging (2014) 1.49
The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression. Neuroimage Clin (2015) 1.48
A comparison of CT- and MR-based attenuation correction in neurological PET. Eur J Nucl Med Mol Imaging (2014) 0.96
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis. Molecules (2015) 0.92
Aminonaphthalene 2-cyanoacrylate (ANCA) probes fluorescently discriminate between amyloid-β and prion plaques in brain. J Am Chem Soc (2012) 0.87
Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2015) 0.86
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease? Eur J Nucl Med Mol Imaging (2015) 0.84
Cerebral [(18) F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy. Transl Psychiatry (2016) 0.84
Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging (2015) 0.82
Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET. Eur J Nucl Med Mol Imaging (2013) 0.82
A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst) (2015) 0.81
PiB-Conjugated, Metal-Based Imaging Probes: Multimodal Approaches for the Visualization of β-Amyloid Plaques. ACS Med Chem Lett (2013) 0.81
Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study. Eur J Nucl Med Mol Imaging (2016) 0.80
Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn (2015) 0.79
Preliminary Characterization and In Vivo Studies of Structurally Identical (18)F- and (125)I-Labeled Benzyloxybenzenes for PET/SPECT Imaging of β-Amyloid Plaques. Sci Rep (2015) 0.78
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal (2013) 0.78
Molecular imaging of Alzheimer disease pathology. AJNR Am J Neuroradiol (2014) 0.78
Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging (2013) 0.78
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review. BMC Geriatr (2016) 0.77
Gd(3+) complexes conjugated to Pittsburgh compound B: potential MRI markers of β-amyloid plaques. J Biol Inorg Chem (2013) 0.77
Amyloid-β probes: Review of structure-activity and brain-kinetics relationships. Beilstein J Org Chem (2013) 0.77
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging (2017) 0.77
Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. J Cereb Blood Flow Metab (2015) 0.76
Discovery of a novel fluorescent probe for the sensitive detection of β-amyloid deposits. Biosens Bioelectron (2015) 0.76
Recent advances in neuroimaging biomarkers in geriatric psychiatry. Curr Psychiatry Rep (2013) 0.76
Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study. EJNMMI Res (2017) 0.75
The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using (18)F-AV45: Is Amyloid the Principal Actor in the Disease? Dement Geriatr Cogn Dis Extra (2014) 0.75
PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis (2016) 0.75
Advances in development of fluorescent probes for detecting amyloid-β aggregates. Acta Pharmacol Sin (2016) 0.75
Evaluation of [(11) C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT. Synapse (2016) 0.75
The cingulate cortex of older adults with excellent memory capacity. Cortex (2016) 0.75
Identifying Multimodal Intermediate Phenotypes Between Genetic Risk Factors and Disease Status in Alzheimer's Disease. Neuroinformatics (2016) 0.75
Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden. Eur J Nucl Med Mol Imaging (2017) 0.75
Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images. Front Aging Neurosci (2017) 0.75
Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates. J Biol Inorg Chem (2015) 0.75
A new integrated dual time-point amyloid PET/MRI data analysis method. Eur J Nucl Med Mol Imaging (2017) 0.75
A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages. Neuroimage (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging (1997) 7.54
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Screening for dementia by memory testing. Neurology (1988) 3.93
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology (1999) 3.49
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol (2011) 2.84
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology (2007) 2.61
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med (2011) 1.54
Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci Methods (2008) 1.46
2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med (2007) 1.37
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain (2008) 1.34
Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biol Psychiatry (2010) 1.29
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study. Nucl Med Biol (2010) 1.16
The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience. Q J Nucl Med Mol Imaging (2009) 1.02
Diagnostic validity of a standardized neuropsychological battery derived from Luria's neuropsychological tests. J Consult Clin Psychol (1978) 0.95
Scoring the Stroop test. Acta Psychol (Amst) (1965) 0.90
[Validation of a brief screening scale evaluating praxic abilities for use in memory clinics. Evaluation in 419 controls, 127 mild cognitive impairment and 320 demented patients]. Rev Neurol (Paris) (2009) 0.89
Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm (Vienna) (2011) 0.88
Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease. J Neurol Sci (2009) 0.87
Picture confrontation oral naming: performance differences between aphasics and normals. Brain Lang (1996) 0.82
Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET. J Neurol (2009) 0.81
Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease. Nucl Med Biol (2010) 0.80
Voxel-based analysis of amyloid positron emission tomography probe [C]BF-227 uptake in mild cognitive impairment and alzheimer's disease. Dement Geriatr Cogn Disord (2010) 0.80
Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging (2009) 5.98
ESPEN guidelines for nutrition screening 2002. Clin Nutr (2003) 5.22
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage (2001) 3.87
Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology (2003) 3.60
Description of 1,108 older patients referred by their physician to the "Geriatric Frailty Clinic (G.F.C) for Assessment of Frailty and Prevention of Disability" at the gerontopole. J Nutr Health Aging (2014) 3.37
Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage (2005) 3.28
Regional differences in semen quality in Europe. Hum Reprod (2001) 3.19
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology (2001) 2.78
Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev (1996) 2.58
Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging (2008) 2.54
The I.A.N.A Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging (2008) 2.53
Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry (2006) 2.48
Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. J Nutr Health Aging (2013) 2.44
Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). J Gerontol A Biol Sci Med Sci (2001) 2.43
The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem (1998) 2.35
Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain (2007) 2.17
Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology (2010) 1.99
Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism (1997) 1.97
The functional neuroanatomy of episodic memory: the role of the frontal lobes, the hippocampal formation, and other areas. Neuroimage (1998) 1.92
Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry (2009) 1.86
Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. J Nutr Health Aging (2009) 1.85
A PET study of photophobia during spontaneous migraine attacks. Neurology (2010) 1.81
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin (2002) 1.78
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci (2001) 1.72
Uterine artery embolization in the primary treatment of uterine leiomyomas: technical features and prospective follow-up with clinical and sonographic examinations in 58 patients. AJR Am J Roentgenol (2000) 1.71
The primary care physician and Alzheimer's disease: an international position paper. J Nutr Health Aging (2010) 1.68
Posterior cerebral hypoperfusion in migraine without aura. Cephalalgia (2008) 1.67
The structural components of music perception. A functional anatomical study. Brain (1997) 1.66
Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology (2004) 1.65
Protein-energy oral supplementation in malnourished nursing-home residents. A controlled trial. Age Ageing (2000) 1.63
The use of fibrin tissue adhesive to reduce blood loss and the need for blood transfusion after total knee arthroplasty. A prospective, randomized, multicenter study. J Bone Joint Surg Am (1999) 1.61
FDG accumulation and tumor biology. Nucl Med Biol (1998) 1.59
Recommendations for ICT use in Alzheimer's disease assessment: Monaco CTAD Expert Meeting. J Nutr Health Aging (2013) 1.57
A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing (1994) 1.56
Time to pregnancy and semen parameters: a cross-sectional study among fertile couples from four European cities. Hum Reprod (2002) 1.55
Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. J Intern Med (2013) 1.52
The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain (1998) 1.49
Instrumental activities of daily living as a potential marker of frailty: a study of 7364 community-dwelling elderly women (the EPIDOS study). J Gerontol A Biol Sci Med Sci (2001) 1.47
Central auditory processing in aging: the dichotic listening paradigm. J Nutr Health Aging (2010) 1.44
IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging (2007) 1.44
Episodic memory in transient global amnesia: encoding, storage, or retrieval deficit? J Neurol Neurosurg Psychiatry (1999) 1.42
Health and nutritional promotion program for patients with dementia (NutriAlz Study): design and baseline data. J Nutr Health Aging (2009) 1.40
Minimum data set for nutritional intervention studies in the elderly IAG/ IANA task force consensus. J Nutr Health Aging (2004) 1.40
Functional consequences of the sustained or transient activation by Bax of the mitochondrial permeability transition pore. J Biol Chem (1999) 1.40
Voxel-based mapping of brain hypometabolism in permanent amnesia with PET. Neuroimage (2001) 1.39
The Mini Nutritional Assessment (MNA) for grading the nutritional state of elderly patients: presentation of the MNA, history and validation. Nestle Nutr Workshop Ser Clin Perform Programme (1999) 1.36
Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Mol Psychiatry (2013) 1.30
Prospective study of restriction of activity in old people after falls. Age Ageing (1987) 1.28
Derivation and validation of a mortality-risk index from a cohort of frail elderly patients hospitalised in medical wards via emergencies: the SAFES study. Eur J Epidemiol (2008) 1.28
IANA (International Academy on Nutrition and Aging) Expert Group: weight loss and Alzheimer's disease. J Nutr Health Aging (2007) 1.28
PepT1-mediated epithelial transport of dipeptides and cephalexin is enhanced by luminal leptin in the small intestine. J Clin Invest (2001) 1.27
alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem (1996) 1.26
Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry. Neuropsychologia (2008) 1.25
Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry (2010) 1.24
Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids (2001) 1.20
Sperm morphological defects related to environment, lifestyle and medical history of 1001 male partners of pregnant women from four European cities. Hum Reprod (2001) 1.20
Advantages of dietary, exercise-related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin Interv Aging (2010) 1.17
Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett (1999) 1.16
Recurrent septic shock due to Streptococcus suis. J Clin Microbiol (1998) 1.16
The practice of obtaining approval from medical research ethics committees: a comparison within 12 European countries for a descriptive study on acetylcholinesterase inhibitors in Alzheimer's dementia. Eur J Neurol (2005) 1.15
Brain kinetics and specific binding of [11C]PK 11195 to omega 3 sites in baboons: positron emission tomography study. Eur J Pharmacol (1991) 1.15
Semen quality and male reproductive health: the controversy about human sperm concentration decline. APMIS (2001) 1.15
Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging (2006) 1.15
Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/MRI correlative study. J Neurol Neurosurg Psychiatry (2001) 1.14
Management of osteoporosis in the elderly. Curr Med Res Opin (2009) 1.14
Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochem Biophys Res Commun (1998) 1.13
Alzheimer disease: protective factors. Am J Clin Nutr (2000) 1.13
Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. J Nutr (1994) 1.12
Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway. J Biol Chem (1999) 1.11
Implementing frailty into clinical practice: we cannot wait. J Nutr Health Aging (2012) 1.11
The New Mexico aging process study (1979-2003). A longitudinal study of nutrition, health and aging. J Nutr Health Aging (2007) 1.10
Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev Med Child Neurol (1998) 1.10
Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage (1998) 1.10
Intra- and inter-individual variability in human sperm concentration, motility and vitality assessment during a workshop involving ten laboratories. Hum Reprod (2000) 1.09
Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr (1998) 1.09
Aging society and gerontechnology: a solution for an independent living? J Nutr Health Aging (2014) 1.09
Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Biotechnology (N Y) (1995) 1.09
Serum vitamin D deficiency as a predictor of incident non-Alzheimer dementias: a 7-year longitudinal study. Dement Geriatr Cogn Disord (2012) 1.09
Malnutrition and falls. Lancet (1990) 1.08
Prospective sonographic assessment of uterine artery embolization for the treatment of fibroids. Ultrasound Obstet Gynecol (2002) 1.07
Neurotensin and neuromedin N stimulate mucin output from human goblet cells (Cl.16E) via neurotensin receptors. Am J Physiol (1992) 1.07
Apathy and cortical atrophy in Alzheimer's disease. Int J Geriatr Psychiatry (2010) 1.07
Prospective evaluation of time-of-flight MR angiography in the follow-up of intracranial saccular aneurysms treated with Guglielmi detachable coils. J Comput Assist Tomogr (1999) 1.07
Weight loss in Alzheimer disease. Am J Clin Nutr (2000) 1.07
[Cortical malformations and epilepsy: Role of MR imaging]. J Radiol (2006) 1.06
The integration of frailty into clinical practice: preliminary results from the Gérontopôle. J Nutr Health Aging (2012) 1.06
Healthy aging, memory subsystems and regional cerebral oxygen consumption. Neuropsychologia (1995) 1.05
Stimulation of proteoglycan synthesis by glucuronosyltransferase-I gene delivery: a strategy to promote cartilage repair. Proc Natl Acad Sci U S A (2004) 1.05
Motor behaviour deficits and their histopathological and functional correlates in the nigrostriatal system of dopamine transporter knockout mice. Neuroscience (2003) 1.04